Transcriptome profiling reveals that VNPP433‐3β, the lead next‐generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial–mesenchymal transition and stem cell markers
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.